Equities Analysts Set Expectations for Zai Lab Q1 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Zai Lab in a research report issued to clients and investors on Thursday, February 20th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share. Leerink Partnrs also issued estimates for Zai Lab’s Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Separately, Cantor Fitzgerald upgraded Zai Lab to a “strong-buy” rating in a report on Wednesday, February 5th.

Zai Lab Stock Performance

ZLAB stock opened at $32.95 on Monday. The firm has a market cap of $3.61 billion, a P/E ratio of -11.90 and a beta of 1.02. Zai Lab has a 1 year low of $13.48 and a 1 year high of $36.60. The stock has a 50-day simple moving average of $27.03 and a 200-day simple moving average of $25.44.

Insiders Place Their Bets

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the sale, the insider now owns 33,834 shares in the company, valued at $889,157.52. This trade represents a 18.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 13.88% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zai Lab

A number of institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in shares of Zai Lab in the fourth quarter worth $29,000. Pictet Asset Management Holding SA acquired a new stake in shares of Zai Lab in the 4th quarter valued at about $31,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Zai Lab by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock worth $1,496,000 after purchasing an additional 1,200 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Zai Lab by 15.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company’s stock worth $290,000 after purchasing an additional 1,502 shares during the last quarter. Finally, Invesco Ltd. grew its stake in Zai Lab by 4.2% in the fourth quarter. Invesco Ltd. now owns 44,340 shares of the company’s stock worth $1,161,000 after purchasing an additional 1,790 shares in the last quarter. 41.65% of the stock is owned by institutional investors and hedge funds.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.